NASDAQ:AIMD Ainos Q1 2025 Earnings Report $1.70 -0.02 (-1.16%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.70 0.00 (-0.24%) As of 05/15/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ainos EPS ResultsActual EPS-$1.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAinos Revenue ResultsActual Revenue$0.11 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAinos Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time9:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ainos Earnings HeadlinesAIMD Using AI Technology to Advance Semi ManufacturingMay 14 at 2:59 PM | finance.yahoo.comAinos, Inc.: Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure MarketsMay 14 at 9:59 AM | finanznachrichten.deSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 17 at 1:00 AM | Brownstone Research (Ad)Ainos, Inc.: Ainos Updates Standard Industrial Classification Code to Reflect Smell AI Business FocusMay 11, 2026 | finanznachrichten.deAinos, Inc.: VASRO: Ainos Expands Smell AI from Industrials into Healthcare Infrastructure, Reinforcing AI Infrastructure Positioning and Multi-Vertical ScalabilityApril 17, 2026 | finanznachrichten.deAinos stock jumps 5% on healthcare AI expansion plansApril 17, 2026 | in.investing.comSee More Ainos Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email. Email Address About AinosAinos (NASDAQ:AIMD) (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations. The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis. In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials. Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.View Ainos ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingRobinhood, SoFi, and Webull Are Telling Very Different StoriesViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying Opportunity Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
